Therapeutic Asset Ratings
686 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
ERIBULIN MONOMETHANESULFONATE
Breast Cancer
Henan Cancer Hospital
P4
BB
(69)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
Breast Cancer
SWOG Cancer Research Network
P4
BB
(69)
Palbociclib
Breast Cancer
Hoffmann-La Roche
P4
BB
(69)
TAMOXIFEN
Breast Cancer
Dana-Farber Cancer Institute
P4
BB
(69)
VITAMIN D
Breast Cancer
University of Illinois at Chicago
P4
BB
(69)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Breast Cancer
Ospedale di Camposampiero
P4
BB
(68)
Eloxatin
Breast Cancer
Beijing Biostar Pharmaceuticals Co., Ltd.
P4
BB
(68)
FLUOROURACILUM
Breast Cancer
Pfizer
P4
BB
(68)
Inno-206
Breast Cancer
George Washington University
P4
BB
(68)
Ribociclib
Breast Cancer
National Cancer Institute (NCI)
P4
BB
(68)
Zoladex
Breast Cancer
TerSera Therapeutics LLC
P4
BB
(68)
Arimidex
Breast Cancer
National Cancer Institute (NCI)
P4
BB
(67)
Capecitabine
Breast Cancer
University of Vermont Medical Center
P4
BB
(67)
Carboplatin
Breast Cancer
Akeso
P4
BB
(67)
Cyclophosphamide
Breast Cancer
Fudan University
P4
BB
(67)
Docetaxel
Breast Cancer
Fudan University
P4
BB
(67)
Epirubicin
Breast Cancer
Ohio State University Comprehensive Cancer Center
P4
BB
(67)
Eribulin
Breast Cancer
Sun Yat-sen University
P4
BB
(67)
Everolimus
Breast Cancer
UNC Lineberger Comprehensive Cancer Center
P4
BB
(67)
EXEMESTANE
Breast Cancer
National Cancer Institute (NCI)
P4
BB
(67)
FILGRASTIM
Breast Cancer
MedSIR
P4
BB
(67)
FULVESTRANT
Breast Cancer
MedSIR
P4
BB
(67)
Irinotecan
Breast Cancer
Pfizer
P4
BB
(67)
Letrozole
Breast Cancer
National Cancer Institute (NCI)
P4
BB
(67)
LEUPROLIDE
Breast Cancer
Fudan University
P4
BB
(67)
Showing 1 to 25 of 686 assets
Previous
Page 1 of 28
Next